NCT07193589View on ClinicalTrials.gov

A Phase II Clinical Study Evaluating of ZL-82 Tablets in Atopic Dermatitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Atopic Dermatitis
Interventions
DRUG

The high-dose group of ZL-82 tablets

Participants will take the investigational drug orally for 16 weeks, 200mg each time , once a day.

DRUG

The low-dose group of ZL-82 tablets

Participants will take the investigational drug orally for 16 weeks, 100mg each time, once a day.

DRUG

The placebo group

The participants will take the investigational drug orally for 16 weeks, 2 tablets each time , once a day.

Trial Locations (1)

610200

West China Hospital Sichuan University, Chengdu

All Listed Sponsors
lead

Chengdu Zenitar Biomedical Technology Co., Ltd

INDUSTRY